TIES Study: Observational study of HIV-infected infants in the United States who initiate antiretroviral therapy (ART) at less than 6 weeks of age.

TIES

The Treating Infants Early Study (TIES) is an observational study of HIV-infected infants in the United States who initiate antiretroviral therapy (ART) at less than 6 weeks of age. The primary objective of the study is to assess the safety and plasma HIV RNA response to early-initiated ART. The secondary objective is to establish a cohort of infants who, with well characterized clinical histories and banked specimens, will be candidates for future studies of HIV reservoirs and remission. For more information about TIES, visit ties.ucsf.edu.

TIES shares many of the same objectives as the IMPAACT P1115 study, and IMPAACT is delighted that the study is now underway. In addition, because TIES offers the opportunity to enroll infants who may not qualify for P1115, IMPAACT sites in the United States are strongly encouraged to take part in the study. Please contact the TIES team for more information on how to get started.

Study documents:

  • TIES Study Protocol V1 -3 December 2015

  • Provider Information Sheet

  • Patient Information Sheet

  • Study Contacts:

    Principal Investigator: Theodore Ruel

    DAIDS Medical Officer: Devasena Gnanashanmugam

    NICHD Medical Officer: Rohan Hazra

     

    Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.